Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014
Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014
复制标题
DOI：
10.1093/cid/ciw571
复制
发表时间：
2016-11-15
影响因子：
11.8
通讯作者：
Jiang, Jia-Fu
中科院分区：
文献类型：
--
作者：
Bai, Chang-Qing;Mu, Jin-Song;Jiang, Jia-Fu
背景资料。2014-2015年间，埃博拉病毒病(EVD)疫情席卷西非部分地区。目前还没有批准的抗病毒药物可用于治疗埃博拉病毒。对塞拉利昂-中国友谊医院的埃博拉患者进行了回顾性的临床病例系列研究。确诊的EVD患者于2014年10月10日至30日先后入选并接受世界卫生组织(WHO)推荐的支持性治疗(对照组)，或于2014年11月1日至10日接受WHO推荐的治疗加法维拉韦(T-705)治疗。观察对照组85例和T-705治疗组39例患者的存活率和病毒学特征。T-705治疗组总生存率高于对照组(56.4%[22/39]vs 35.3%[30/85]；P=0.027)。在完成所有设计终点观察的35例患者中，T-705治疗组的生存率(64.8%[11/17])高于对照组(27.8%[5/18])。治疗组平均生存时间(46.9±-5.6天)明显长于对照组(28.9±-4.7天)。治疗组患者多数症状明显改善。此外，接受T-705治疗的患者中，52.9%的患者病毒载量降低了100倍，而对照组患者的这一比例仅为16.7%。使用T-705治疗EVD与延长存活期和显著降低病毒载量有关，这为进一步用T-705治疗EVD进行随机对照试验提供了令人信服的理由。
Background. During 2014-2015, an outbreak of Ebola virus disease (EVD) swept across parts of West Africa. No approved antiviral drugs are available for Ebola treatment currently.Methods. A retrospective clinical case series was performed for EVD patients in Sierra Leone-China Friendship Hospital. Patients with confirmed EVD were sequentially enrolled and treated with either World Health Organization (WHO)-recommended supportive therapy (control group) from 10 to 30 October, or treated with WHO-recommended therapy plus favipiravir (T-705) from 1 to 10 November 2014. Survival and virological characteristics were observed for 85 patients in the control group and 39 in the T-705 treatment group.Results. The overall survival rate in the T-705 treatment group was higher than that of the control group (56.4% [22/39] vs 35.3% [30/85]; P=.027). Among the 35 patients who finished all designed endpoint observations, the survival rate in the T-705 treatment group (64.8% [11/17]) was higher than that of the control group (27.8% [5/18]). Furthermore, the average survival time of the treatment group (46.9 +/- 5.6 days) was longer than that of the control group (28.9 +/- 4.7 days). Most symptoms of patients in the treatment group improved significantly. Additionally, 52.9% of patients who received T-705 had a >100-fold viral load reduction, compared with only 16.7% of patients in the control group.Conclusions. Treatment of EVD with T-705 was associated with prolonged survival and markedly reduced viral load, which makes a compelling case for further randomized controlled trials of T-705 for treating EVD.